PDF(Pubmed)
Abstract：
OBJECTIVE: To evaluate the effect of topical carbonic anhydrase inhibitor (brinzolamide) versus placebo on visual function and waveforms in infantile nystagmus syndrome (INS).
METHODS: Prospective, placebo-controlled, double-blind, cross-over study.
METHODS: Setting- A tertiary eye care center. Patients- Cases of idiopathic INS with and without abnormal head posture aged ≥10 years who had not received previous treatment for nystagmus. Intervention- Patients were randomized into two groups. Group 1 was given placebo for 3 months, and after a washout period of 7 days started on topical brinzolamide for the next 3 months. In group 2, the order was reversed. The drops were administered topically three times (every 8 hours) in both eyes. Outcome measure- Binocular best corrected visual acuity (BCVA) using the ETDRS chart, eXpanded nystagmus acuity function (NAFX) score and INS waveforms obtained from eye movement recordings, intraocular pressure (IOP) by Goldmann applanation tonometer, near stereopsis by TNO stereo test, and change in abnormal head posture before and after intervention in the null position.
RESULTS: A total of 29 cases completed the study (23 with abnormal head posture; 6 without abnormal head posture).
A significant improvement was noted in INS waveform characteristics, mean NAFX score (P < 0.001), and mean binocular visual acuity (P < 0.001) with topical brinzolamide in comparison to baseline as well as placebo. No significant change in head position and stereopsis was noted. No side effects were reported with 3 months of brinzolamide therapy.
CONCLUSIONS: While brinzolamide shows improvement in visual acuity and NAFX score in idiopathic INS, its clinical significance needs further evidence.
METHODS: Prospective, placebo-controlled, double-blind, cross-over study.
METHODS: Setting- A tertiary eye care center. Patients- Cases of idiopathic INS with and without abnormal head posture aged ≥10 years who had not received previous treatment for nystagmus. Intervention- Patients were randomized into two groups. Group 1 was given placebo for 3 months, and after a washout period of 7 days started on topical brinzolamide for the next 3 months. In group 2, the order was reversed. The drops were administered topically three times (every 8 hours) in both eyes. Outcome measure- Binocular best corrected visual acuity (BCVA) using the ETDRS chart, eXpanded nystagmus acuity function (NAFX) score and INS waveforms obtained from eye movement recordings, intraocular pressure (IOP) by Goldmann applanation tonometer, near stereopsis by TNO stereo test, and change in abnormal head posture before and after intervention in the null position.
RESULTS: A total of 29 cases completed the study (23 with abnormal head posture; 6 without abnormal head posture).
A significant improvement was noted in INS waveform characteristics, mean NAFX score (P < 0.001), and mean binocular visual acuity (P < 0.001) with topical brinzolamide in comparison to baseline as well as placebo. No significant change in head position and stereopsis was noted. No side effects were reported with 3 months of brinzolamide therapy.
CONCLUSIONS: While brinzolamide shows improvement in visual acuity and NAFX score in idiopathic INS, its clinical significance needs further evidence.
摘要：
目的：评估局部碳酸酐酶抑制剂（布林佐胺）与安慰剂对婴儿眼震综合征（INS）视觉功能和波形的影响。
方法：前瞻性，安慰剂对照,双盲,交叉研究。
方法：设置-三级眼部护理中心。患者-年龄≥10岁且未接受过眼球震颤治疗的特发性INS伴或不伴异常头部姿势的病例。干预-将患者随机分为两组。第1组给予安慰剂3个月，在7天的洗脱期后，在接下来的3个月内开始外用布林佐胺。在第2组中，顺序相反。在双眼中局部施用滴剂三次(每8小时)。结果测量-使用ETDRS图的双眼最佳矫正视力（BCVA），从眼动记录获得的扩展眼震敏锐度函数(NAFX)评分和INS波形，Goldmann压平眼压计的眼内压（IOP），通过TNO立体测试近立体视，以及在零位干预前后异常头部姿势的变化。
结果：共29例完成研究（头部姿势异常23例；头部姿势无异常6例）。
显著改善了INS波形特性，平均NAFX评分（P<0.001），与基线和安慰剂相比，局部布林佐胺的平均双眼视力（P<0.001）。头部位置和立体视没有明显变化。3个月的布林佐胺治疗没有副作用。
结论：虽然布林佐胺在特发性INS中显示出视力和NAFX评分的改善，其临床意义需要进一步的证据。
方法：前瞻性，安慰剂对照,双盲,交叉研究。
方法：设置-三级眼部护理中心。患者-年龄≥10岁且未接受过眼球震颤治疗的特发性INS伴或不伴异常头部姿势的病例。干预-将患者随机分为两组。第1组给予安慰剂3个月，在7天的洗脱期后，在接下来的3个月内开始外用布林佐胺。在第2组中，顺序相反。在双眼中局部施用滴剂三次(每8小时)。结果测量-使用ETDRS图的双眼最佳矫正视力（BCVA），从眼动记录获得的扩展眼震敏锐度函数(NAFX)评分和INS波形，Goldmann压平眼压计的眼内压（IOP），通过TNO立体测试近立体视，以及在零位干预前后异常头部姿势的变化。
结果：共29例完成研究（头部姿势异常23例；头部姿势无异常6例）。
显著改善了INS波形特性，平均NAFX评分（P<0.001），与基线和安慰剂相比，局部布林佐胺的平均双眼视力（P<0.001）。头部位置和立体视没有明显变化。3个月的布林佐胺治疗没有副作用。
结论：虽然布林佐胺在特发性INS中显示出视力和NAFX评分的改善，其临床意义需要进一步的证据。
